Anju Singhal, MD
Critical Care Medicine · Falls Church, VANPI 1861636755
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Vertex at 49.0% of the total. 2025 is the largest year on record at $7,929, more than ten times the $143 reported in 2020. Among critical care medicine clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 231 payments — averaging $54.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$6K
- United Therapeutics Corporation$2K
- Actelion Pharmaceuticals US, Inc.$543
- Bayer$456
- Insmed, Inc.$447
- Boehringer Ingelheim$317
- plus $3K from 31 others
Across 17 payments — averaging $79.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$1K
What the payments were for
- Consulting fees$4,88038%
- Travel & lodging$9538%
- Food & beverage$6,86754%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 15 | $6,223 |
| United Therapeutics Corporation | 58 | $1,517 |
| Actelion Pharmaceuticals US, Inc. | 14 | $543 |
| Bayer | 21 | $456 |
| Insmed, Inc. | 17 | $447 |
| Boehringer Ingelheim | 18 | $317 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $279 |
| Mylan Specialty L.p. | 7 | $278 |
| Paratek Pharmaceuticals, Inc. | 8 | $265 |
| AbbVie | 9 | $219 |
| Electromed, Inc. | 5 | $217 |
| Merck | 5 | $161 |
| Astellas Pharma US Inc | 5 | $156 |
| Davol Inc. | 1 | $150 |
| ANI Pharmaceuticals, Inc. | 5 | $145 |
| Johnson & Johnson | 2 | $137 |
| Gilead | 2 | $132 |
| Vifor Pharma, Inc. | 3 | $130 |
| Viatris Specialty LLC | 1 | $128 |
| AstraZeneca | 1 | $125 |
| GSK | 1 | $124 |
| Kamada Ltd. | 1 | $110 |
| Melinta Therapeutics, LLC | 4 | $73 |
| Sandoz | 2 | $56 |
| Shionogi Inc | 2 | $45 |
| La Jolla Pharmaceutical Company | 2 | $41 |
| Genentech USA, Inc. | 2 | $33 |
| Alcresta Therapeutics, Inc. | 1 | $29 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Baxter Healthcare | 1 | $19 |
| Vivus LLC | 1 | $19 |
| Advanced Respiratory, Inc | 1 | $18 |
| CMP Pharma, Inc. | 1 | $17 |
| Invivyd Inc | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Eurofins Viracor, LLC | 1 | $16 |
| Philips North America LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,700 in reported general payments places this provider in the 90th percentile of 174 critical care medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 72 | $1,869,295 |
| OfevNintedanib Esylate | 35 | $573,055 |
| Tyvaso DpiTreprostinil | 18 | $423,560 |
| Pirfenidone | 24 | $87,155 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $24,437 |
| Sildenafil Citrate | 28 | $22,204 |
| Atovaquone | 13 | $6,481 |
| Mycophenolate Mofetil | 17 | $3,717 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $709 |
| Prednisone | 98 | $581 |
| Mirtazapine | 30 | $566 |
| Pantoprazole Sodium | 26 | $501 |
| Azithromycin | 16 | $453 |
| Montelukast Sodium | 19 | $452 |
| Famotidine | 16 | $433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta | $6,223 | $1,869,29572 claims |
| Boehringer IngelheimOfev | $317 | $573,05535 claims |
| GSKTrelegy Ellipta | $124 | $24,43736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 174 critical care medicine providers in Virginia.
Other critical care medicine in Falls Church
- Oksana ShlobinFalls Church$375K
- Sami Abdul JawadFalls Church$193K
- Christopher KingFalls Church$131K
- Duy DuongFalls Church$10K
- Mehul DesaiFalls Church$9K
- Christopher ThomasFalls Church$8K
- Markos KashiourisFalls Church$4K
- Ahmad Abdul-AzizFalls Church$2K
- James LantryFalls Church$1K
- Eric BonuraFalls Church$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.